Drug candidate for memory loss associated with Alzheimer’s developed
A drug called CMS121 given to mice with Alzheimer's-like disease treated their memory loss, allowing them to perform the same as healthy control mice in tests.
List view / Grid view
A drug called CMS121 given to mice with Alzheimer's-like disease treated their memory loss, allowing them to perform the same as healthy control mice in tests.
Researchers suggest the SRPX2 protein, which inhibits complement system-dependent synapse removal could be a target for novel Alzheimer’s and schizophrenia therapies.
The novel aryl hydrocarbon receptor (AHR) inhibiting drug slowed zika virus replication and prevented mouse foetuses malforming in infected mothers.
Which immune cells contribute towards immune-induced neurodegeneration and how could this knowledge enable conditions such Alzheimer’s and multiple sclerosis to be treated?
Researchers show that the mutated huntingtin protein associated with Huntington’s disrupts the transport of essential proteins within the neuron, potentially highlighting an early cause of the disease.
The researchers suggest the regions they identified in their study could be targeted to improve dysfunctional behaviours associated with autism spectrum disorders, even in adults.
Researchers report COVID-19 can cause a range of severe neurological symptoms, which may be the main presentation of COVID-19 in some patients.
The vitamin K-based drug has a unique structure which researchers believe makes it effective in controlling even medication-resistant seizures.
Researchers have synthesised three oligonucleotide inhibitor molecules which stopped seizures in mouse models, making them potential epilepsy drugs.
By administering a one-time PTB antisense oligonucleotide therapy to mice, researchers observed an increase in neurons and elimination of Parkinson's from the models.
Japanese researchers have shown that a silicon-based antioxidant agent can suppress the development of kidney failure and Parkinson's disease in rodent models.
Researchers have found that a neurofilament named NfL is heightened in COVID-19 patients who require ventilator treatment, so could serve as a biomarker for the disease.
The team found that the expression of the APOE4 gene variant in pericytes caused amyloid plaque formation in a blood-brain barrier model.
The team found microglia and CD8 T cells were vital to protecting neurons from vesicular stomatitis virus (VSV) infection and suggest loss of taste and smell in COVID-19 could be due to a certain mechanism of infection.
Administering a novel complement protein blocker (B4Crry) alongside reperfusion therapy improved cognitive and motor recovery in a model of ischemic stroke.